ABSTRACT
Objective: To determine the stability of parathyroid hormone in patients with chronic kidney disease both in serum and ethylenediaminetetraacetic acid [EDTA] plasma tested at room temperature
Methods: This is a prospective study conducted at Princess Iman Centre for Research and Laboratory Sciences, King Hussein Medical Center Jordan. A total of 94 patients were included with age range between 10 years and 65 years, of which 42.5% male and 57.5% were female. From each patient 5 ml EDTA acid and 10 ml gel separator [with clot activator] tubes were collected and analyzed in a time period between 1/7/2015 and 1/11/2015. The plasma and sera were analyzed for intact parathyroid hormone within 6 hours of collection [baseline] and after 48 hours stored at room temperature, using immulite 2000 intact parathyroid hormone assay. Mean parathyroid hormone value, median, and differences for sera and EDTA samples at baseline and after 48 hours of collection were calculated and evaluated using Microsoft excel sheet
Results: Serum samples analysed after 48 hours from the collection time showed significant difference in their mean concentration value from the baseline mean value. Regarding EDTA acid plasma samples, their analysis after 48 hours showed a little decrease in parathyroid hormone concentration from the baseline value, which was not significantly different. The percentage of difference between baseline mean value and 48 hours mean value was 7.91% for EDTA acid plasma samples and 11.1% for serum samples
Conclusion: The study showed that the parathyroid hormone was more stable in EDTA acid plasma sample than serum at baseline and after 48 hours of collection at room temperature. Serum samples gave inaccurate and false low results. Therefore, plasma measurement for parathyroid hormone analysis is preferred and advised. However, reference range for PTH concentration in plasma should be established if it is needed to be adopted for routine clinical use
ABSTRACT
Objective: to assess the frequency of aberrant antigens expression in acute leukemias and their possible prognostic significance in a group of Jordanian patients
Methods: a retrospective study of acute leukemia cases was conducted at King Hussein Medical Centre over 3 years [January 2012 to December 2014]. A total of 368 cases of acute leukemia diagnosed by multi parameter flow cytometry performed on peripheral blood and/ or fresh bone marrow aspirates. The co-expression of myeloid markers on lymphoblasts and lymphoid markers on myeloblasts was analyzed. The findings were correlated with remission status
Results: 368 cases of acute leukemias were retrieved; these were: 192 [52%] cases of acute myeloid leukemia [AML], 173 cases [47%] of acute lymphoblastic leukemia [ALL] and 3 cases [1%] with mixed phenotype acute leukemia. Aberrant immunophenotype expression was observed in 44 [23%] AML cases and in 50 [29%] of ALL cases. CD7 was the commonest aberrant lymphoid marker expressed in AML which was noted in 19/44 [43%]. Of the aberrant B-ALL cases, CD33 were expressed in 18/38 [47%] and CD13 in 14/38 [37%]. 212 out of 368 cases [58%] were followed up in our centre during treatment program and stratified into remission and non-remission groups based on morphologic assessment of peripheral blood and bone marrow aspirates. These tests were carried out at day 21 of induction therapy, completion of treatment and any clinical deterioration during the study period. 70% of non-remission ALL and 53% of non-remission AML had aberrant phenotypes. No significant differences were noted between classical and aberrant acute leukemias regarding age, sex and blasts count
Conclusion: the incidence of aberrant antigen expression in acute leukemia was comparable with most published international data. Such aberrant antigen expression may represent a poor prognostic indicator among this group of Jordanian patients. These findings may help to recognize patients with high risk group and low remission rate. Further studies are needed to confirm the correlation between aberrant phenotypes with prognosis and therapeutic response of acute leukemia
ABSTRACT
Objective: To compare serological and molecular assays for detection hepatitis B virus infection
Methods: A total of two hundreds patient were included with age range between 20 years and 60 years. Samples were obtained to detect serological markers of HBV infection using Enzyme linked immunosorbent assay [ELISA] and for HBV DNA quantitation through performing real time polymerase chain reaction [PCR]
Results: Of two hundreds samples tested by ELISA for HBsAg, 186 [93%] were positive and 14 [7%] samples were negative, the results had been confirmed by PCR where 1 sample showed false positive results and 2 false negative. The specificity, sensitivity, positive predictive value, and negative predictive value for ELISA were calculated: 92%, 99%, 99%, and 86% respectively
Conclusion: ELISA is a reliable and relatively not expensive method for detection HBV, though PCR quantitation represents the gold standard assay for this purpose. Combining both methods in clinical practice ensure applying best laboratory practice if enough resources are available
ABSTRACT
To identify the importance of flow cytometry [FCM] in diagnosis and subclassifying acute lymphoblastic leukemia, and to highlight its capability to detect antigen aberration. The Results of flow cytometry for 165 patients, between January 2006 and December 2011 who were diagnosed with acute lymphoblastic leukemia [ALL] were retrospectively reviewed with respect to age and gender distribution and immunophenotypic findings. 63% of patients were children [104 out of 165 patients] with age less than fourteen years old. 114 patients were male while 51 patients were female with male to female ratio 2.2: 1. Precursor-B- acute lymphoblastic leukemia represents eighty percent [132 patients] of cases, of 106 patients [87.6%] were [CD10/CD19] positive, 125 patients [94.7%] were positive for cytoplasmic CD79a, 126/129 [97.6%] were positive for HLA-DR, and 15 patients [11.36%] were CD10 negative. Aberrant myeloid antigen expression was noted; CD33 and CD13 were positive in 15/113 [13.3%] and 2/108 [1.85%] respectively. On the other hand precursor-T- acute lymphoblastic leukemias were found in thirty three patients, 84.4% of them were Anti-TdT positive, and all were negative for B-cell markers. Myeloid antigen expression results were as follows; 1/29 [3.4%] and 2/29 [6.9%] positive for CD33 and CD 13 respectively. Flow cytometry is a golden tool in diagnosis and identifying ALL subtypes. Precursor-B- acute lymphoblastic leukemia represents most of ALL cases with minority of cases are CDlOnegative. Aberrant myeloid antigen expression would not change the diagnosis of ALL in either B- or T- subtypes. Further clinical correlation is needed to figure out aberrant markers prognostic implications
ABSTRACT
We report on a 28 year old female who was diagnosed as a case of Behcet's syndrome and referred to our rheumatology clinic for further evaluation regarding unexplained fever and leukocytosis. Blood film revealed anemia and persistent eosinophilia. Bone marrow examination showed eosinophilic leukemia which is a rare condition especially in the female gender. Although Behcet syndrome can be associated with eosinophilia, the clinical picture was suggestive of myeloid neoplasm
ABSTRACT
We report a case of Pseudo-Thrombocytopenia among an eleven years old female patient who was referred as a case of Isolated Thrombocytopenia. Complete blood count revealed thrombocytopenia; a blood film was prepared and showed numerous platelet aggregations. Complete Blood Count was repeated in different tubes with different anticoagulants and also showed thrombocytopenia. Cases of thrombocytopenia should be carefully examined; the peripheral blood morphology should be one of the first tests to be ordered to exclude Pseudo-Thrombocytopenia as well as other hematological disorders